{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:03:30Z","timestamp":1772805810241,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.amjcard.2019.09.037","type":"journal-article","created":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T17:36:33Z","timestamp":1574012193000},"page":"82-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Variation in Placebo Effect on Health-Related Quality of Life in Heart Failure (from the TOPCAT Trial)"],"prefix":"10.1016","volume":"125","author":[{"given":"Muhammad Shahzeb","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas P.","family":"Kalogeropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2019.09.037_bib0001","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","article-title":"A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST)","volume":"134","author":"Califf","year":"1997","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2019.09.037_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1071-9164(98)90502-4","article-title":"Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) trial investigators","volume":"4","author":"Massie","year":"1998","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2019.09.037_bib0003","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.jacc.2008.07.056","article-title":"Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program","volume":"52","author":"Blair","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.09.037_bib0004","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2009.03.036","article-title":"Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: a propensity-matched study of the EPHESUS trial","volume":"143","author":"Pitt","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2019.09.037_bib0005","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jacc.2012.10.025","article-title":"Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial","volume":"61","author":"Butler","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.09.037_bib0006","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jama.1995.03520440040034","article-title":"Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries: results from the GUSTO trial: Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries","volume":"273","author":"Van de Werf","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2019.09.037_bib0007","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.09.037_bib0008","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Pitt BRegional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.09.037_bib0009","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.114.001937","article-title":"Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial","volume":"9","author":"Lewis","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2019.09.037_bib0010","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/0002-8703(90)90062-3","article-title":"The placebo effect in heart failure","volume":"120","author":"Packer","year":"1990","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2019.09.037_bib0011","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the kansas city cardiomyopathy questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.09.037_bib0012","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/eurjhf\/hft071","article-title":"Preferences of heart failure patients in daily clinical practice: quality of life or longevity?","volume":"15","author":"Kraai","year":"2013","journal-title":"Eur J Heart Fail"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919311063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919311063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:31:50Z","timestamp":1757572310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914919311063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0002914919311063"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.09.037","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variation in Placebo Effect on Health-Related Quality of Life in Heart Failure (from the TOPCAT Trial)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.09.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}